natgillin/translations-raw huggingface dataset:
In psoriasis patients treated with infliximab as a maintenance regimen in the absence of concomitant immunomodulators, approximately 28% developed antibodies to infliximab (see section 4.4: "
Približno 28% bolesnika s psorijazom liječenih infliksimabom kao terapijom održavanja bez istodobnog liječenja imunomodulatorima razvilo je protutijela na infliksimab (vidjeti dio 4.4: "
In psoriasis patients treated with infliximab as a maintenance regimen in the absence of concomitant immunomodulators, approximately 28% developed antibodies to infliximab (see section 4.4: “
Približno 28% bolesnika s psorijazom liječenih infliksimabom kao terapijom održavanja bez istodobnog liječenja imunomodulatorima razvilo je protutijela na infliksimab (vidjeti dio 4.4: "
In psoriasis patients, treatment with infliximab resulted in decreases in epidermal inflammation and normalization of keratinocyte differentiation in psoriatic plaques.
U bolesnika s psorijazom, liječenje infliksimabom dovelo je do smanjenja upale u epidermalnom sloju i normalizacije diferencijacije keratocita u psorijatičnim plakovima.
In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 response from baseline at Week 16 (see Tables 11 and 12).
U ispitivanjima Psoriasis Study I i II primarni ishod bio je udio bolesnika u kojih je od početka ispitivanja do 16. tjedna postignut odgovor PASI 75 (vidjeti Tablice 11 i 12).
In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 response from baseline at Week 16 (see Tables 13 and 14).
U ispitivanjima Psoriasis Study I i II primarni ishod bio je udio bolesnika u kojih je od početka ispitivanja do 16. tjedna postignut odgovor PASI 75 (vidjeti Tablice 13 i 14).
In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 response from baseline at Week 16 (see Tables 13 and14).
U ispitivanjima Psoriasis Study I i II primarni ishod bio je udio bolesnika u kojih je od početka ispitivanja do 16. tjedna postignut odgovor PASI 75 (vidjeti Tablice 13 i 14).
In psoriasis studies, the safety and efficacy of Cosentyx in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated (see also section 4.5).
U ispitivanjima psorijaze, sigurnost i djelotvornost Cosentyxa u kombinaciji s imunosupresivima, što uključuje i biološke lijekove, ili s fototerapijom nisu bile ocjenjivane (vidjeti također dio 4.5).
In psoriasis studies, the safety and efficacy of STELARA in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated.
U ispitivanjima psorijaze, sigurnost primjene i djelotvornost STELARE u kombinaciji s imunosupresivima, uključujući biološke lijekove ili fototerapiju, nije procijenjena.
In Psoriasis Study 1 maintenance of PASI 75 was significantly superior with continuous treatment compared with treatment withdrawal (p < 0.001).
U Ispitivanju psorijaze 1, održavanje PASI vrijednosti 75 znatno je bolje uz stalno liječenje u usporedbi s prekinutim liječenjem (p < 0,001).
In Psoriasis Study 1, at week 2 and week 12, significantly greater improvements from baseline were demonstrated in the DLQI in each ustekinumab treatment group compared with placebo.
U Ispitivanju psorijaze 1, u tjednu 2 i tjednu 12, pokazano je značajno veće poboljšanje u odnosu na početne vrijednosti dermatološkog indeksa kvalitete života (DLQI) u svim grupama liječenim ustekinumabom u usporedbi s placebom.
In Psoriasis Study I, 28% of patients who were PASI 75 responders and were re-randomised to placebo at Week 33 compared to 5% continuing on Humira, p<0.001, experienced “loss of adequate response” (PASI score after Week 33 and on or before Week 52 that resulted in a <PASI 50 response relative to baseline with a minimum of a 6-point increase in PASI score relative to Week 33).
U ispitivanju Psoriasis Study I, u 28% bolesnika s odgovorom PASI 75 kojima je nakon 33. tjedna pri ponovnoj randomizaciji dodijeljen placebo, u usporedbi s 5% bolesnika koji su nastavili uzimati lijek Humira (p<0,001), uočen je „gubitak primjerenog odgovora“ (PASI rezultat nakon 33. i u ili prije 52. tjedna koji je rezultirao odgovorom < PASI 50 u odnosu na početak terapije, uz porast PASI rezultata za najmanje 6 bodova u odnosu na 33. tjedan).
In psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies, less than 1% of patients treated with Cosentyx developed antibodies to secukinumab up to 52 weeks of treatment.
U kliničkim ispitivanjima psorijaze, psorijatičnog artritisa i ankilozantnog spondilitisa, manje od 1% bolesnika liječenih Cosentyxom razvilo je protutijela na sekukinumab do 52. tjedna liječenja.
In Psoriatic Arthritis Study 1 (PsA Study 1) and Psoriatic Arthritis Study 2 (PsA Study 2) 29% and 35% of patients, respectively, were previously treated with an anti-TNFα agent and discontinued the anti-TNFα agent for either lack of efficacy or intolerance (anti-TNFα-IR patients).
U prvom ispitivanju psorijatičnog artritisa (1. ispitivanje PsA) odnosno drugom ispitivanju psorijatičnog artritisa (2. ispitivanje PsA) 29% odnosno 35% bolesnika prethodno je bilo liječeno anti-TNFα lijekom i prekinulo je primjenu anti-TNFα lijeka ili zbog nedostatka djelotvornosti ili zbog intolerancije (anti-TNFα-NO bolesnici).
In psoriatic arthritis, Leflunomide Winthrop has been compared with placebo in 186 patients over six months.
U slučaju psorijatičnog artritisa, Leflunomide Winthrop je uspoređen s placebom u 186 bolesnika tijekom razdoblja od šest mjeseci.
In psoriatic arthritis, Leflunomide Winthrop was more effective than placebo, with 59% of the patients taking Leflunomide Winthrop responding to treatment, compared with 30% of those taking placebo.
U slučaju psorijatičnog artritisa, Leflunomide Winthrop je bio djelotvorniji od placeba, pri čemu je 59 % bolesnika koji su uzimali lijek Leflunomide Winthrop odgovorilo na liječenje, u usporedbi sa 30 % onih koji su uzimali placebo.
In psoriatic arthritis: leflunomide therapy is started with a loading dose of 100 mg once daily for 3 days.
U bolesnika s psorijatičnim artritisom: liječenje leflunomidom započinje primjenom udarne doze od 100 mg jedanput na dan tijekom 3 dana.
In psoriatic arthritis: leflunomide therapy is started with a loading dose of 100 mg once daily for 3 days.
U bolesnika sa psorijatičnim artritisom: liječenje leflunomidom započinje primjenom udarne doze od 100 mg jedanput na dan tijekom 3 dana.
In published literature reports, cases of non-mandibular osteonecrosis have been observed in patients under the age of 18 years treated with Avastin (please see section 5.3).
U izvješćima objavljenima u literaturi zabilježeni su slučajevi osteonekroze koja nije zahvaćala čeljust u bolesnika mlađih od 18 godina liječenih lijekom Avastin (vidjeti dio 5.3).
In pulmonary arterial hypertension and heart failure, in the absence of endothelin receptor antagonism, elevated ET- 1 concentrations are strongly correlated with the severity and prognosis of these diseases.
Kod plućne arterijske hipertenzije i zatajenja srca, u odsustvu antagonista endotelinskih receptora, povišene koncentracije ET-1 strogo su povezane s težinom i prognozom tih bolesti.
In pulmonary arterial hypertension and heart failure, in the absence of endothelin receptor antagonism, elevated ET-1 concentrations are strongly correlated with the severity and prognosis of these diseases.
Kod plućne arterijske hipertenzije i zatajenja srca, u odsustvu antagonista endotelinskih receptora, povišene koncentracije ET-1 strogo su povezane s težinom i prognozom tih bolesti.
In pulmonary arterial hypertension patients, the oral bioavailability of sildenafil after 80 mg three times a day was on average 43 % (90 % CI: 27 % -60 %) higher compared to the lower doses.
U bolesnika s plućnom arterijskom hipertenzijom je bioraspoloživost sildenafila nakon peroralne primjene doze od 80 mg tri puta na dan bila u prosjeku 43% (90% CI: 27% - 60%) veća u usporedbi s nižim dozama.
In pulmonary arterial hypertension patients, there may be a potential for increased risk of bleeding when sildenafil is initiated in patients already using a Vitamin K antagonist, particularly in patients with pulmonary arterial hypertension secondary to connective tissue disease.
U bolesnika s plućnom arterijskom hipertenzijom postoji mogućnost povećanog rizika od krvarenja kada se započinje liječenje sildenafilom u bolesnika koji već uzimaju antagonist vitamina K, osobito u onih bolesnika u kojih je plućna arterijska hipertenzija posljedica bolesti vezivnog tkiva. .
In pulmonary arterial hypertension, studies with riociguat have been mainly performed in forms related to idiopathic or heritable PAH and PAH associated with connective tissue disease.
U plućnoj arterijskoj hipertenziji, ispitivanja s riocigvatom provedena su većinom u idiopatskio ili nasljednom PAH-u i PAH-u povezanom s bolešću vezivnog tkiva.
In pulmonary arterial hypertension, studies with riociguat have been mainly performed in forms related to idiopathic or heritable PAH and PAH associated with connective tissue disease.
U plućnoj arterijskoj hipertenziji, ispitivanja s riocigvatom provedena su većinom u idiopatskom ili nasljednim PAH-u i PAH-u povezanom s bolešću vezivnog tkiva.
In pulmonary hypertension patients there is increased likelihood for respiratory tract bleeding, particularly among patients receiving anticoagulation therapy.
U bolesnika s plućnom hipertenzijom povećana je vjerojatnost krvarenja u dišnom sustavu, osobito u bolesnika koji primaju antikoagulantne terapije.
In pulmonary hypertension patients there is increased likelihood for respiratory tract bleeding, particularly among patients receiving anticoagulation therapy.
U bolesnika s plućnom hipertenzijom povećana je vjerojatnost krvarenja u dišnom sustavu, osobito u bolesnika koji primaju antikoagulantnu teraoiju.
In RA patients the most common and consistently reported treatment-related adverse reactions associated with Kineret were ISRs.
Najčešće i dosljedno prijavljene nuspojave povezane s liječenjem Kineretom u bolesnika s RA bile su reakcije na mjestu primjene (ISR).
In RA patients, ALT and AST levels should be monitored every 4 to 8 weeks for the first 6 months of treatment followed by every 12 weeks thereafter.
Kod bolesnika s RA, razine ALT-a i AST-a moraju se određivati svakih 4 do 8 tjedana tijekom prvih 6 mjeseci liječenja te svakih 12 tjedana nakon toga.
In RA patients, assessment of lipid parameters should be performed 4 to 8 weeks following initiation of RoActemra therapy.
Kod bolesnika s RA vrijednosti lipida moraju se odrediti 4 do 8 tjedana nakon početka liječenja lijekom RoActemra.
In RA patients, no unexpected accumulation of anakinra was observed after daily subcutaneous doses for up to 24 weeks.
U bolesnika s RA nije primijećeno neočekivano nakupljanje nakon supkutanih doza lijeka primjenjivanih dnevno u trajanju do 24 tjedna.
In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and CRP (mg/dl) values) improved at 24 or 26 weeks compared to placebo.
U ispitivanjima RA I – IV sve pojedinačne komponente kriterija ACR odgovora (broj bolnih i otečenih zglobova, liječnikova i bolesnikova ocjena aktivnosti bolesti i boli, indeks onesposobljenosti (HAQ) i razine CRP-a (mg/dl)) pokazale su poboljšanje nakon 24 ili 26 tjedana primjene lijeka
In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and CRP (mg/dl) values) improved at 24 or 26 weeks compared to placebo.
U ispitivanjima RA I – IV sve pojedinačne komponente kriterija ACR odgovora (broj bolnih i otečenih zglobova, liječnikova i bolesnikova ocjena aktivnosti bolesti i boli, indeks onesposobljenosti (HAQ) i razine CRP-a (mg/dl)) pokazale su poboljšanje nakon 24 ili 26 tjedana primjene lijeka Humira u odnosu na placebo.
In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses compared to placebo as early as one to two weeks after initiation of treatment.
U ispitivanjima RA I – IV, bolesnici liječeni lijekom Humira postigli su statistički značajno bolje odgovore ACR 20 i 50 u usporedbi s placebom već jedan do dva tjedna nakon početka liječenja.
In RA study III, most subjects who achieved improvement in physical function and continued treatment maintained improvement through Week 520 (120 months) of open-label treatment.
U ispitivanju RA III, kod većine koji su postigli poboljšanje fizičke funkcije i nastavili liječenje održano je poboljšanje tijekom 520 tjedana (120 mjeseci) otvorenog liječenja.
In RA study IV, the ACR 20 response of patients treated with Humira plus standard of care was statistically significantly better than patients treated with placebo plus standard of care (p < 0.001).
U ispitivanju RA IV, ACR 20 odgovor u bolesnika liječenih lijekom Humira uz standardnu skrb bio je statistički značajno bolji nego u bolesnika koji su primali placebo uz standardnu skrb (p<0,001).
In RA study V, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (see Table 5).
U ispitivanju RA V, strukturno oštećenje zglobova procjenjivalo se radiološki, a izraženo je promjenom ukupnog zbroja bodova prema Sharpu (Tablica 5).
In RA study V, structural joint damage was assessed radiographically and expressed as change in modified total Sharp Score (see Table 7).
U ispitivanju RA V, strukturno oštećenje zglobova procjenjivalo se radiološki, a izraženo je promjenom ukupnog zbroja bodova prema Sharpu (Tablica 7).
In RA study V, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (see Table 9).
U ispitivanju RA V, strukturno oštećenje zglobova procjenjivalo se radiološki, a izraženo je promjenom ukupnog zbroja bodova prema Sharpu (Tablica 9).
In RA-I and RA-II, Cimzia-treated patients reported significant improvements in physical function as assessed by the Health Assessment Questionnaire – Disability Index (HAQ-DI) and in tiredness (fatigue) as reported by the Fatigue Assessment Scale (FAS) from Week 1 through to the end of the studies compared to placebo.
U RA-I i RA-II, u skupini bolesnika liječenih Cimzijom zabilježena su značajna poboljšanja fizikalne funkcije ocijenjeno Upitnikom za procjenu zdravlja - indeks nesposobnosti (HAQ-DI) i umora određenog Ljestvicom za procjenu umora (FAS) od 1. tjedna do kraja ispitivanja, u usporedbi s placebom.
In rabbit studies with bazedoxifene, abortion and an increased incidence of heart (ventricular septal defect) and skeletal system (ossification delays, misshapen or misaligned bones, primarily of the spine and skull) anomalies in the fetuses were present at maternally toxic dosages of  0.5 mg/kg/day (1.5 times the human exposure).
U ispitivanjima bazedoksifena na kunićima, pri dozama toksičnima za majku od 0,5 mg/kg na dan (1,5 puta veća izloženost nego u ljudi), zabilježeni su u pobačaji i povećana incidencija anomalija srca (defekt ventrikularnog septuma) i koštanog sustava ploda (odgođeno okoštavanje, deformacija ili krivi raspored kostiju, prvenstveno kralježnice i lubanje).
In rabbits abortion occurred in conjunction with maternal toxicity at exposures below the human therapeutic range.
Kod kunića je došlo do pobačaja zajedno s toksičnosti za majku pri izloženostima ispod ljudskog terapijskog raspona.
In rabbits doses of 50 or 100 U/kg intravenous on days 8 and 9 of gestation induced viable fetuses with congenital malformations: no NOEL has been determined.
U kunića doze od 50 ili 100 U/kg intravenski 8. i 9. dana gestacije inducirale su vijabilne fetuse s kongenitalnim malformacijama: NOEL nije utvrđen.
In rabbits, abortion and a low rate of ventricular septal defects (≥ 0.1 mg/kg) and hydrocephaly (≥ 10 mg/kg) were seen.
U kunića su opaženi pobačaji te niska stopa defekata ventrikularnog septuma ( 0,1 mg/kg) i hidrocefalija ( 10 mg/kg).
In rabbits, abortion and a low rate of ventricular septal defects ( 0.1 mg/kg) and hydrocephaly ( 10 mg/kg) were seen.
U kunića su opaženi pobačaji te mali postotak defekata ventrikularnog septuma ( 0,1 mg/kg) i hidrocefalija ( 10 mg/kg).
In rabbits, cabozantinib produced foetal soft tissue changes (reduced spleen size, small or missing intermediate lung lobe) and increased foetal incidence of total malformations.
U kunića je kabozantinib uzrokovao promjene u mekom tkivu fetusa (smanjena veličina slezene, smanjenje ili gubitak srednjeg plućnog krila) te povećanu incidenciju ukupnih malformacija u fetusa.
In rabbits, coadministration was poorly tolerated in many mothers, resulting in death, moribundity or abortion.
Istodobna primjena je slabo podnesena među skotnim ženkama kunića, što je rezultiralo smrću, pobolom i pobačajem.
In rabbits, developmental toxicity was observed only at maternally toxic doses (see section 5.3).
U kunića je razvojna toksičnost uočena samo pri dozama toksičnim za majku (vidjeti dio 5.3.).
In rabbits, Econor was investigated in a field study involving 1,152 weaned rabbits.
Kod zečeva je Econor ispitivan u okviru terenske studije koja je uključivala 1 152 mladih zečeva koji su tek prestali sisati.
In rabbits, IVEMEND caused initial transient local acute inflammation following paravenous, subcutaneous and intramuscular administration.
U kunića je IVEMEND nakon paravenske, supkutane i intramuskularne primjene uzrokovao prolaznu lokalnu akutnu upalu.
In rabbits, maternal toxicity (decreased food consumption, scant/no faeces/urine, suppressed body weight gain) was observed at 1000 mg/kg (0.74 times the 50 mg human clinical exposure when administered in combination with abacavir and lamivudine based on AUC).
U kunića je toksičnost za majku (smanjen unos hrane, slabo izlučivanje/izostanak izlučivanja fecesa/mokraće, suprimiran prirast tjelesne težine) primijećena pri primjeni doze od 1000 mg/kg (izloženost 0,74 puta veća od kliničke izloženosti u ljudi pri primjeni doze od 50 mg u kombinaciji s abakavirom i lamivudinom, što je utvrđeno na temelju AUC-a).
In rabbits, oral, maternally toxic, doses of brinzolamide of up to 6 mg/kg/day (261 times the recommended daily clinical dose of 23 µg/kg/day) revealed no effect on foetal development.
Peroralne doze brinzolamida do 6 mg/kg/dan koje su iskazivale maternalnu toksičnost (261 puta veće od preporučene dnevne kliničke doze od 23 g/kg/dan), nisu utjecale na fetalni razvoj kunića.
In rabbits, reductions in gravid uterine weights and number of live foetuses were due to increases in the number of resorptions, increases in post-implantation loss and complete litter loss in 4 of 6 pregnant females at plasma exposure levels 3 times the systemic exposure in humans.
U kunića je smanjenje težine gravidnih uterusa te broja živih fetusa bilo posljedica povećanog broja resorpcija, povećanih gubitaka ploda nakon implantacije te gubitka čitavog legla u 4 od 6 gravidnih ženki, pri ekspoziciji koncentracijama u plazmi 3 puta većima od sistemske izloženosti u ljudi.
In rabbits, systemic exposure at the high dose level was only 0.3 times human exposure at the maximum clinical dose and thus the development toxicity of fosamprenavir has not been fully determined.
Sistemska izloženost kod kunića pri visokim dozama bila je samo 0,3 puta od one koju nalazimo kod izloženosti ljudi pri maksimalnoj kliničkoj dozi te stoga razvojna toksičnost fosamprenavira nije u cijelosti utvrđena.
In rabbits, the component nucleotide, 2’-fluorouridine is found in plasma and urine after single radiolabeled pegaptanib intravenous and intravitreal doses.
U kunića je nakon jedne radioaktivno označene intravenske i intravitrealne doze pegaptaniba u plazmi i mokraći pronađena komponenta nukleotida, 2’-fluorouridin.
In RAISE and TRA100773B studies, in the subgroup of ITP patients with baseline platelet count
U ispitivanjima RAISE i TRA100773B, u podgrupi bolesnika s ITP-om s početnim brojem trombocita
In randomised clinical studies, a subcutaneous dose of 23 MU/m2/day (230 micrograms/m2/day) or rather 4-8.4 micrograms/kg/day was used.
U randomiziranim kliničkim ispitivanjima supkutano je primjenjivana doza od 23 MU/m2/dan (230 mikrograma/m2/dan) ili još češće 4–8,4 mikrograma/kg/dan.
In randomised clinical trials, a subcutaneous dose of 230 microgram/m2/day (4.0 to 8.4 microgram/kg/day) was used.
U randomiziranim kliničkim ispitivanjima supkutano je primjenjivana doza od 230 mikrograma/m2/dan (od 4,0 do 8,4 mikrograma/kg/dan).
In randomised clinical trials, a subcutaneous dose of 230 micrograms/m2/day (4.0 to 8.4 micrograms/kg/day) was used.
U randomiziranim kliničkim ispitivanjima korištene su supkutane doze od 230 mikrograma/m2/dan (4,0 do 8,4 mikrograma/kg/dan).
In randomised clinical trials, a subcutaneous dose of 230 μg/m2/day (4.0 to 8.4 μg/kg/day) was used.
U randomiziranim kliničkim ispitivanjima primijenjena je supkutana doza od 230 μg/m2 na dan (4,0 do 8,4 μg/kg na dan).
In randomised, controlled, double-blind clinical trials (including developmental and postmarketing experience), over 17,000 patients with type 2 diabetes have been treated with Onglyza .
U randomiziranim, kontroliranim, dvostruko slijepim kliničkim ispitivanjima (uključujući iskustvo tijekom razvoja lijeka i nakon njegova stavljanja u promet) lijekom Onglyza je liječeno više od 17 000 bolesnika sa šećernom bolešću tipa 2.
In randomised, controlled, double-blind clinical trials (including developmental and postmarketing experience), over 17,000 patients with type 2 diabetes have been treated with Onglyza.
U randomiziranim, kontroliranim, dvostruko slijepim kliničkim ispitivanjima (uključujući iskustvo tijekom razvoja lijeka i nakon njegova stavljanja u promet) lijekom Onglyza je liječeno više od 17 000 bolesnika sa šećernom bolešću tipa 2.
In randomised, controlled, double-blind clinical trials (including developmental and postmarketing experience), over 17,000 patients with type 2 diabetes have been treated with saxagliptin.
U randomiziranim, kontroliranim, dvostruko slijepim kliničkim ispitivanjima (uključujući iskustvo tijekom razvoja lijeka i nakon njegova stavljanja u promet) saksagliptinom je bilo liječeno više od 17 000 bolesnika sa šećernom bolešću tipa 2.
In randomised, placebo-controlled clinical trials, filgrastim did not increase the incidence of undesirable effects associated with cytotoxic chemotherapy.
U randomiziranim, placebom kontroliranim kliničkim ispitivanjima, filgrastim nije povećao incidenciju neželjenih učinaka povezanih s citotoksičnom kemoterapijom.
In rare and exceptional cases, subcutaneous infusion of 250-350 IU/kg was able to produce therapeutic protein C plasma levels in patients with no intravenous access.
U rijetkim i iznimnim slučajevima, potkožna infuzija od 250-350 IU/kg je postigla terapeutske razine proteina C u plazmi kod pacijenata bez intravenskog pristupa.
In rare and exceptional cases, subcutaneous infusion of 250-350 IU/kg was able to produce therapeutic protein C plasma levels in patients with no intravenous access.
U rijetkim i iznimnim slučajevima, potkožna infuzija od 250-350 IU/kg je postigla terapijske razine proteina C u plazmi kod pacijenata bez intravenskog pristupa.
In rare and exceptional cases, subcutaneous infusion of 250-350 IU/kg was able to produce therapeutic protein C plasma levels in patients with no intravenous access.
U rijetkim i iznimnim slučajevima, supkutana infuzija od 250-350 IU/kg je postigla terapijske razine proteina C u plazmi kod pacijenata bez intravenskog pristupa.